HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Pancreatic ductal adenocarcinoma — Clinical Guidelines

Overview

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by poor prognosis due to late diagnosis and resistance to treatment. Recent advancements in chemotherapy have shown improved outcomes, prompting exploration of surgical interventions for selected cases with metastatic disease 1.

Diagnosis

Imaging: CT, MRI, and endoscopic ultrasound (EUS) for tumor staging and detection of metastases 1.

Biopsy: Histopathological confirmation via biopsy or surgical resection 1 8.

Markers: Limited utility; CEA expression is absent in PDAC but present in chronic pancreatitis 9.

Specialized Pathological Assessment: Intraoperative frozen section analysis by subspecialized pathologists may improve accuracy 8.

Management

First-Line Treatment: Chemotherapy (e.g., FOLFIRINOX, gemcitabine-based regimens) for unresectable disease 1 6.

Adjunctive Therapies:

- Immunotherapy: Bacterial-based approaches using Listeria monocytogenes for immune reactivation 3. - Targeted Therapy: Multikinase inhibitors like trametinib and nintedanib to remodel the tumor microenvironment 5. - Radiation: Stereotactic body radiation therapy (SBRT) for isolated local recurrence post-surgery, with potential benefit when combined with maintenance chemotherapy 7.

Surgical Considerations: Conversion surgery or resection of oligometastases in selected patients with favorable response to neoadjuvant therapy 1.

Special Populations

Access to Care: Disparities in access to specialized cancer consultations and cancer-directed therapies exist, influenced by sociodemographic factors 6.

No Specific Recommendations: Limited evidence provided for pregnancy, pediatrics, or elderly-specific management in the abstracts [].

Key Recommendations

Chemotherapy as Standard Initial Therapy: Initiate with systemic chemotherapy for unresectable PDAC, considering regimens like FOLFIRINOX or gemcitabine-based treatments (Evidence: Strong 1 6).

Consider Conversion Surgery in Selected Cases: Evaluate patients with a favorable response to neoadjuvant therapy for potential conversion surgery or resection of oligometastases (Evidence: Moderate 1).

Utilize SBRT for Isolated Local Recurrence: Employ stereotactic body radiation therapy for isolated local recurrence post-surgery, especially when combined with maintenance chemotherapy (Evidence: Moderate 7).

Enhance Access to Specialized Care: Improve access to specialized oncology consultations to ensure receipt of cancer-directed therapies (Evidence: Moderate 6).

References

1 Hashimoto D, Satoi S, Fujii T, Sho M, He J, Hackert T et al.. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2023. link 2 Ali SMA, Adnan Y, Ali SM, Ahmad Z, Chawla T, Farooqui HA. Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma. Journal of cancer research and clinical oncology 2023. link 3 . A Bacterial-Based Immunotherapy for PDAC. Cancer discovery 2022. link 4 . Collagen I Homotrimers Promote PDAC Growth and Impact Immunity. Cancer discovery 2022. link 5 . Multikinase Inhibition Induces Tumor Microenvironment Remodeling in PDAC. Cancer discovery 2022. link 6 Mavros MN, Coburn NG, Davis LE, Mahar AL, Liu Y, Beyfuss K et al.. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2019. link 7 Ryan JF, Groot VP, Rosati LM, Hacker-Prietz A, Narang AK, McNutt TR et al.. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. Annals of surgical oncology 2018. link 8 Liu YJ, Smith-Chakmakova F, Rassaei N, Han B, Enomoto LM, Crist H et al.. Frozen Section Interpretation of Pancreatic Margins: Subspecialized Gastrointestinal Pathologists Versus General Pathologists. International journal of surgical pathology 2016. link 9 Albers GH, Fleuren G, Escribano MJ, Nap M. Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma. American journal of clinical pathology 1988. link

Pancreatic ductal adenocarcinoma